Ozempic vs Saxenda

Ozempic (semaglutide) and Saxenda (liraglutide 3 mg) are both GLP-1 receptor agonists manufactured by Novo Nordisk, but they are approved for different primary indications and represent different generations of the drug class. Ozempic is FDA-approved for type 2 diabetes and is injected once weekly, while Saxenda is FDA-approved for chronic weight management and requires daily injections. Both medications are frequently discussed in the context of weight loss, with Ozempic often used off-label for this purpose.

The STEP 8 trial provided a direct head-to-head comparison of injectable semaglutide 2.4 mg (the Wegovy dose) versus liraglutide 3 mg (the Saxenda dose) for weight management over 68 weeks. Semaglutide produced mean weight loss of approximately 15.8%, compared to 6.4% with liraglutide. Semaglutide also demonstrated a higher percentage of participants achieving clinically meaningful weight loss thresholds of 10%, 15%, and 20%. While this trial used the Wegovy dose of semaglutide rather than the standard Ozempic dose, the results illustrate the substantial efficacy advantage of semaglutide over liraglutide.

Both medications cause gastrointestinal side effects, with nausea being the most commonly reported. Saxenda has a longer history of FDA-approved use specifically for weight management and more extensive post-market safety data in that indication. However, its daily injection requirement and lower efficacy have led many clinicians and patients to favor semaglutide-based options. Insurance coverage, out-of-pocket cost, and approved indications vary significantly. Patients should consult their healthcare provider to determine which medication is most appropriate given their diagnosis, treatment goals, and access considerations.